AI Article Synopsis
- Ultrasonography isn't very effective for spotting endometrial issues in postmenopausal patients on tamoxifen.
- Significant differences were found between two sets of patients: one with increased endometrial thickness and one without, showing higher pathology rates in the first group after further ultrasound tests.
- The study concluded that an increase in endometrial thickness in these patients is linked to a higher likelihood of endometrial pathology, including cancer.
Article Abstract
Background: Ultrasonography has a limited value in endometrial assessment for identification of endometrial pathologies in postmenopausal tamoxifen-treated patients.
Methods: We compared the rate of endometrial pathologies and the mean +/- SD of endometrial thickness diagnosed after the first and second transvaginal ultrasonographic studies performed on 55 postmenopausal tamoxifen-treated patients with secondary endometrial thickening (Group I). This rate was also compared with 46 similar patients without secondary thickening (Group II). We also compared the mean +/- SD of endometrial thickness detected in various ultrasonographic studies, as well as various clinical features.
Results: A significantly higher rate of endometrial pathologies, including two cases of endometrial cancer identified in gynecologically asymptomatic patients (3.6%), was diagnosed in Group I after the second study compared with the first study (52.7% and 9.1%, respectively; P = 0.001) and compared with those diagnosed after the second study in Group II (30.4%; P = 0.03). There was a significant increase (74.7 +/- 115%) in endometrial thickness after the second study compared with the first study performed on Group I (10.7 +/- 5.53 mm and 16.59 +/- 5.53 mm, respectively; P = 0.0001) and a significant difference in endometrial thickness demonstrated in the second study performed on Groups I and II (16.59 +/- 5.53 mm and 11.4 +/- 3.91 mm, respectively; P = 0.001). There were no significant differences in the time elapsed since the diagnosis of breast carcinoma and from the beginning of tamoxifen treatment to the performance of the first ultrasonographic study as well as the time elapsed between the first and second studies performed.
Conclusions: A significant increase (> 50%) in secondary endometrial thickening, measured ultrasonographically, in postmenopausal tamoxifen-treated patients, is associated with a high rate of endometrial pathologies, including endometrial cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cncr.10587 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial.
J Natl Cancer Inst
December 2024
Department of Oncology and Pathology, Karolinska Institutet, 171 64 Stockholm, Sweden.
Background: Estrogen receptor-positive breast cancer patients have a long-term risk of distant metastatic disease, and premenopausal patients have a higher risk. Randomized studies with long-term follow-up are essential to understand treatment benefit. We elucidated the long-term tamoxifen therapy benefit by menopausal status in the Stockholm tamoxifen trials with 20 years complete follow-up.
View Article and Find Full Text PDFCYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108.
Breast Cancer Res Treat
October 2024
Indiana University School of Medicine, Indianapolis, IN, USA.
Article Synopsis
- - The study examined how genetic variations in the CYP2D6 gene and resulting endoxifen levels affect breast cancer outcomes in patients taking tamoxifen.
- - Conducted with 113 patients with advanced hormone receptor-positive breast cancer, it compared those with poor CYP2D6 metabolism to those with normal or intermediate metabolism regarding progression-free survival (PFS).
- - Results showed no significant relationship between CYP2D6 status, endoxifen concentrations, and PFS, possibly due to the small sample size and issues with sample collection in the trial.
Pharmacogenetics of Toxicities Related to Endocrine Treatment in Breast Cancer: A Systematic Review and Meta-analysis.
Cancer Genomics Proteomics
August 2024
Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter Medical School, Exeter, U.K.
Article Synopsis
- Endocrine therapy is the primary treatment for hormone receptor-positive breast cancer, but it has side effects that lead to poor adherence and lower survival rates.
- A review of 87 studies revealed variability in how pharmacogenomic factors predict treatment-related adverse effects, with a focus primarily on postmenopausal Caucasian women.
- The findings suggest the need for more comprehensive studies that include diverse populations to better understand pharmacogenomics' role in managing endocrine therapy-related toxicities.
Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial.
Cancer Prev Res (Phila)
November 2023
Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California.
Unlabelled: Predicting an individual's risk of treatment discontinuation is critical for the implementation of precision chemoprevention. We developed partly conditional survival models to predict discontinuation of tamoxifen or anastrozole using patient-reported outcome (PRO) data from postmenopausal women with ductal carcinoma in situ enrolled in the NSABP B-35 clinical trial. In a secondary analysis of the NSABP B-35 clinical trial PRO data, we proposed two models for treatment discontinuation within each treatment arm (anastrozole or tamoxifen treated patients) using partly conditional Cox-type models with time-dependent covariates.
View Article and Find Full Text PDFEstrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer.
Clin Cancer Res
September 2022
Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Purpose: Estrogen receptor (ER) expression is a prognostic parameter in breast cancer, and a prerequisite for the use of endocrine therapy. In ER+ early breast cancer, however, no receptor-associated biomarker exists that identifies patients with a particularly favorable outcome. We have investigated the value of ESR1 amplification in predicting the long-term clinical outcome in tamoxifen-treated postmenopausal women with endocrine-responsive breast cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!